As of 2025-07-13, the Intrinsic Value of TRACON Pharmaceuticals Inc (TCON) is 591.58 USD. This TCON valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1.43 USD, the upside of TRACON Pharmaceuticals Inc is 41,269.50%.
The range of the Intrinsic Value is 472.98 - 826.74 USD
Based on its market price of 1.43 USD and our intrinsic valuation, TRACON Pharmaceuticals Inc (TCON) is undervalued by 41,269.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 472.98 - 826.74 | 591.58 | 41269.5% |
| DCF (Growth 10y) | 538.02 - 971.84 | 683.47 | 47695.4% |
| DCF (EBITDA 5y) | 540.76 - 890.38 | 693.32 | 48384.1% |
| DCF (EBITDA 10y) | 579.30 - 1,026.21 | 756.54 | 52804.7% |
| Fair Value | 346.85 - 346.85 | 346.85 | 24,155.54% |
| P/E | 191.79 - 488.11 | 315.86 | 21988.4% |
| EV/EBITDA | 759.49 - 1,866.16 | 1,249.93 | 87307.6% |
| EPV | (930.54) - (1,732.13) | (1,331.33) | -93200.0% |
| DDM - Stable | 117.63 - 215.26 | 166.45 | 11539.6% |
| DDM - Multi | (193.47) - (287.69) | (232.21) | -16338.5% |
| Market Cap (mil) | 0.11 |
| Beta | 3.64 |
| Outstanding shares (mil) | 0.08 |
| Enterprise Value (mil) | -7.78 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.01% |
| Cost of Debt | 20.81% |
| WACC | 13.63% |